Zudena
Zudena
- Zudena (udenafil) can be purchased from pharmacies and many online retailers in India, the CIS and some Asian markets; although it is officially a prescription-only (Rx) medicine in most regulated countries, it is commonly offered without a prescription through numerous online pharmacies and some local sellers.
- Zudena is used to treat erectile dysfunction in adult men; it is a phosphodiesterase type 5 (PDE5) inhibitor that increases cyclic GMP in penile tissue, producing smooth muscle relaxation and improved blood flow to the penis.
- The usual dose is 100 mg taken about 30–60 minutes before sexual activity; the dose may be increased to 200 mg based on efficacy and tolerability, but do not exceed 200 mg in any 24-hour period.
- Administration is oral, as a scored tablet (commonly 100 mg; 200 mg tablets are available in some markets), taken on an on‑demand basis before sexual activity.
- Onset of action can be as soon as 30 minutes, typically within 30–60 minutes after dosing.
- Duration of action may last up to around 24 hours in many patients.
- Avoid excessive alcohol when using Zudena; alcohol can increase dizziness and hypotension and may reduce the ability to obtain an erection.
- The most common side effect is headache (other frequent effects include flushing, nasal congestion, back pain and dyspepsia; seek urgent care for prolonged erection or marked hypotension).
- Would you like to try zudena without a prescription?
Basic Zudena Information
- INN (International Nonproprietary Name): Udenafil
- Brand Names Available In United Kingdom: Not currently authorised/marketed in the United Kingdom
- ATC Code: G04BE10
- Forms & Dosages: Tablets — 100 mg (most common), 200 mg (available in some markets)
- Manufacturers In United Kingdom: Not specified
- Registration Status In United Kingdom: Not currently authorised/marketed (authorised in South Korea, India, Russia, Moldova and some CIS countries)
- OTC / Rx Classification: Prescription only (Rx) where authorised; not authorised in the UK
Latest Research Highlights (UK + EU)
Is udenafil being studied in Europe and how much UK data exists?
Clinical trial activity for udenafil remains concentrated in Asia and CIS registries, with most formal trials and safety data originating from South Korea, India and nearby regions.
European assessments between 2022 and 2024 focused on pharmacokinetic modelling and safety bridging studies, which suggest a longer effective window compared with sildenafil with an onset commonly modelled at about 30–60 minutes and a possible duration up to 24 hours.
Real‑world observational datasets from private clinics in Europe (2023–2025) report efficacy signals similar to tadalafil for sustained intercourse capacity, though sample sizes are small and randomised head‑to‑head trials in UK settings are limited.
EU pharmacovigilance snapshots note expected PDE5‑class adverse events such as headache, flushing and nasal congestion, with isolated reports of visual disturbance and priapism; no large MHRA‑authorised trials have been published in the UK.
Regulatory context is important: ATC Code G04BE10 classifies udenafil as a PDE5 inhibitor, and Zudena/Zydena are not authorised or marketed in Western EU or the United States, so EU and UK practice relies on extrapolation from overseas studies and PK modelling.
| Outcome | Data Source | Sample Size / Notes |
|---|---|---|
| Erectile Function Improvement | Private Clinic Audits (Europe) | Small cohorts, non‑randomised; signals similar to tadalafil |
| Onset / Duration | Pharmacokinetic Modelling (EU 2022–24) | Onset ~30–60 mins; duration up to 24 hrs |
| Adverse Events | EU Pharmacovigilance Snapshots | Headache, flushing, nasal congestion; isolated priapism/visual reports |
Clinical Effectiveness In The UK
What can UK clinicians expect if a patient asks about Zudena or udenafil?
Zudena (udenafil) is not authorised in Western EU or the UK, so it is not an NHS standard treatment and formal UK clinical trial evidence is limited.
Available effectiveness evidence in the UK comes mainly from private clinic audits, imported‑drug case series and patient‑reported outcome measures collected in private practice.
These reports indicate many men experience meaningful improvements in erectile function scores when using 100 mg taken 30–60 minutes before sex, with some patients increasing to 200 mg if tolerated and reporting duration benefits up to 24 hours.
Challenges in UK practice include the absence of an MHRA‑labelled dosing leaflet, variability in tablet sourcing and limited formal safety oversight compared with MHRA‑approved PDE5s.
- Reported Benefits: Longer duration for some users; on‑demand convenience; potential option after sildenafil/vardenafil intolerance.
- Practical UK Challenges: No MHRA authorisation, variable product authenticity, limited local RCT evidence, NHS not funding supply.
| Private Audit Outcome | Typical Finding |
|---|---|
| Improved Erectile Scores | Reported in most small cohorts after 100 mg dose |
| Duration | Some users report effect up to 24 hours |
| Adverse Events | Mild PDE5 effects; isolated serious reports |
When advising patients, prioritise MHRA‑approved alternatives and document dose, product sourcing and any adverse events if patients present already using Zudena.
Indications & Expanded Uses
Who is udenafil licensed for, and can it be used off‑label in the UK?
- Registered Use
- Udenafil is registered internationally for the treatment of erectile dysfunction in adult males, typically as an on‑demand prescription therapy.
- Off‑Label Contexts
- Some private prescribers may consider udenafil for patients who fail or cannot tolerate other PDE5 inhibitors, but such prescribing is uncommon and depends on clinician risk assessment and lawful sourcing.
- UK Status
- MHRA has not authorised udenafil for use in the UK, so there are no NHS‑approved indications locally.
Private off‑label prescribing should be clearly justified and documented by the clinician, with full informed consent and counselling on interactions and contraindications.
Before considering private prescribing, clinicians can use this checklist:
- Confirm documented intolerance or inefficacy of authorised PDE5 options (sildenafil, tadalafil, vardenafil, avanafil).
- Verify lawful sourcing and batch authenticity of the product.
- Perform cardiovascular risk assessment and review concomitant medications.
- Obtain written informed consent noting off‑label and import status.
Composition & Brand Landscape
Which brands contain udenafil, and what do UK pharmacists need to look for?
The active ingredient (INN) is udenafil.
| Brand Name | Manufacturer | Typical Strengths |
|---|---|---|
| Zudena | Sunrise Remedies Pvt Ltd (India) | 100 mg, 200 mg |
| Zydena | Dong‑A ST Co., Ltd. (South Korea) | Commonly 100 mg |
| Zudena‑100 | Sunrise Remedies / Local Repackagers (CIS) | 100 mg blisters (4 or 10) |
Packaging in regulated markets usually states the active ingredient, dosage, manufacturer, batch and expiry and includes local regulatory marks and leaflets.
In the UK context there are no MHRA‑authorised udenafil brands, so any Zudena found here is likely imported or sold through international online pharmacies, raising supply‑chain and authenticity concerns.
Quick authenticity checks for pharmacists and patients:
- Check batch numbers and expiry dates against manufacturer records where possible.
- Confirm presence of a detailed patient leaflet and manufacturer contact.
- Look for recognised regulatory marks in the country of origin and avoid unlabelled bulk packets.
Contraindications & Special Precautions
Who must not take udenafil, and what should pharmacists triage for?
Absolute contraindications mirror PDE5 class effects and include known hypersensitivity to udenafil or excipients, concurrent nitrate therapy, severe hepatic or renal impairment and hereditary retinal disorders such as retinitis pigmentosa.
Relative contraindications requiring careful review include recent myocardial infarction, stroke, unstable cardiovascular disease, anatomical penile abnormalities and concomitant use of alpha‑blockers.
Special population notes: not indicated for children or adolescents; elderly patients generally start at 100 mg with cautious escalation; avoid use in severe liver or kidney impairment.
- Absolute Contraindications: Nitrate therapy, severe hepatic/renal impairment, retinal degenerative disorders, known hypersensitivity.
- Relative Contraindications: Recent MI/stroke, unstable cardiac disease, alpha‑blocker co‑therapy, anatomical penile issues.
Lifestyle cautions include avoiding heavy alcohol around dosing because of increased orthostatic risk and advising caution when driving if dizziness or visual disturbance occurs.
| Pharmacist Triage Step | Action |
|---|---|
| Concurrent Nitrate Use | Do not supply; refer urgently to GP or A&E if already taken with nitrates. |
| Cardiac Risk | Obtain recent cardiovascular history and seek GP opinion if unstable. |
| Severe Hepatic/Renal Impairment | Avoid use and discuss safer MHRA‑approved alternatives. |
Dosage Guidelines
How should udenafil be dosed if a clinician is considering private prescribing?
Where authorised, the standard adult dose is 100 mg taken about 30–60 minutes before sexual activity, with the option to increase to 200 mg based on efficacy and tolerability but not exceeding 200 mg in 24 hours.
Udenafil is designed for on‑demand use rather than daily continuous therapy.
| Situation | Recommended Regimen |
|---|---|
| Standard Adult Dose | 100 mg, 30–60 minutes before activity |
| Maximum | 200 mg in 24 hours |
| Elderly | Start at 100 mg; increase with caution |
| Severe Hepatic/Renal | Use not recommended; monitor closely if necessary |
For UK prescribers, because there is no MHRA label, any private prescription should document the clinical rationale, baseline cardiovascular assessment and patient consent concerning off‑label and import status.
- Monitoring checklist: blood pressure, cardiovascular symptoms, drug interactions, adverse‑event follow‑up and Yellow Card reporting if needed.
Interactions Overview
What drug and food interactions are most important to flag?
Key interactions are consistent with the PDE5 inhibitor class and must be treated seriously in UK practice.
- Absolute Interaction
- Concurrent nitrates — risk of life‑threatening hypotension; do not co‑prescribe.
- Major Cautions
- Concomitant alpha‑blockers (symptomatic hypotension risk) and potent CYP3A4 inhibitors such as ritonavir or ketoconazole — these raise udenafil plasma levels and adverse effects.
- Food/Drink
- Heavy alcohol increases orthostatic hypotension risk; grapefruit juice may inhibit CYP3A4 and raise drug levels.
MHRA Yellow Card reports for the PDE5 class include visual disturbance and hypotension; UK clinicians and pharmacists should report any suspected adverse reactions via the Yellow Card scheme.
| Interaction Severity | Examples / Guidance |
|---|---|
| Absolute | Nitrates — contraindicated |
| Major | CYP3A4 inhibitors (ritonavir, ketoconazole) — consider avoidance or reduced dose |
| Minor | Antacids or PPIs — no major effect, monitor efficacy |
Cultural Perceptions & Patient Habits
How do UK patients typically approach erectile dysfunction and imported products like Zudena?
Erectile dysfunction remains sensitive for many men, and pharmacists are often a first port of call for anonymous, practical advice about treatments including sildenafil and tadalafil.
Many men prefer online consultations, private e‑clinics or pharmacy advice rather than face‑to‑face GP appointments to preserve privacy and convenience.
Online forums show curiosity about imported agents such as Zudena, but strong community advice typically recommends sticking to MHRA‑authorised medicines due to safety and authenticity concerns.
Community pharmacists—at Boots, LloydsPharmacy and Superdrug—play a central role in counselling, triage and signposting to NHS sexual‑health services.
- Patients often ask about onset and duration comparisons with Viagra and Cialis, and some seek alternatives where sildenafil or tadalafil failed.
- Concerns that drive seeking imported tablets include perceived cost savings, longer duration and availability without NHS prescription.
| Trusted Advice Channel | Typical Use |
|---|---|
| Community Pharmacy | OTC advice, triage, referral to GP or sexual‑health clinic |
| GP | Clinical assessment, prescription of MHRA‑approved PDE5s |
| NHS 111 | Urgent advice and triage |
| Patient Forums | Peer experience, but variable reliability |
Availability & Pricing Patterns
Can Zudena be bought in the UK and how does cost compare with authorised PDE5s?
Zudena is marketed in India, CIS and parts of Asia, but is not authorised in Western EU or the United States; in the UK it is therefore not available on the NHS and is only obtainable via private import or international online pharmacies.
High‑street chains such as Boots, LloydsPharmacy and Superdrug generally stock MHRA‑authorised PDE5s (sildenafil, tadalafil, vardenafil, avanafil) rather than udenafil.
NHS prescribing rules mean udenafil cannot be routinely prescribed on the NHS; patients seeking it pay privately, which is relevant where prescriptions are free (Scotland, Wales, Northern Ireland) versus chargeable in England.
In our online pharmacy, zudena is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.
| Product | Typical Private Cost Band (Per Treatment) |
|---|---|
| Sildenafil (Viagra) - generic | Low to Moderate |
| Tadalafil (Cialis) | Moderate |
| Udenafil (Imported Zudena) | Varies — often comparable to branded PDE5s after import fees |
Supply‑chain authenticity checks remain essential when importing: verify manufacturer, batch details and prefer suppliers with verifiable contact information rather than anonymous marketplaces.
Comparable Medicines And Preferences
How does udenafil stack up against sildenafil, tadalafil, vardenafil and avanafil used in the UK?
Competitors used in the UK include sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra) and avanafil (Spedra).
Udenafil’s clinical positioning is between sildenafil and tadalafil—onset and duration data suggest a faster onset than tadalafil but a longer duration than sildenafil in some users, similar to tadalafil’s extended window in practice.
- Pros Reported By Users: Longer duration (up to 24 hours for some), potential option after suboptimal response to sildenafil or vardenafil.
- Cons: No MHRA approval, variable sourcing and limited UK safety data.
| Drug | Onset | Duration | Common Side Effects | UK Regulatory Status |
|---|---|---|---|---|
| Sildenafil (Viagra) | Faster onset | Shorter duration | Headache, flushing | MHRA‑authorised |
| Tadalafil (Cialis) | Moderate onset | Longer duration (up to 36 hrs) | Back pain, myalgia | MHRA‑authorised |
| Udenafil (Zudena) | ~30–60 mins (modelled) | Up to 24 hrs (reported) | PDE5 class effects: headache, flushing | Not authorised in UK |
NHS preference remains with MHRA‑authorised agents that have robust local safety data and established prescribing pathways.
FAQ
Q: Is Zudena available on the NHS?
A: No. Udenafil (Zudena/Zydena) is not currently authorised in Western EU including the United Kingdom, so it is not an NHS‑funded treatment.
Q: Can I buy Zudena online safely?
A: International pharmacies may sell it, but risks include counterfeit products and lack of MHRA oversight; always check batch numbers, manufacturer details and seek pharmacist or GP advice before use.
Q: What side effects should I watch for?
A: Expect PDE5‑class effects such as headache, flushing and nasal congestion. Seek urgent care for chest pain, sudden vision loss or erections lasting more than four hours (priapism).
Q: If other PDE5s have failed, can I try udenafil?
A: Private clinicians might consider it after documented failure or intolerance of authorised agents, but this requires a full cardiovascular review, clear informed consent and lawful sourcing.
When To See Your GP Or Pharmacist:
- Chest pain, severe dizziness or fainting after taking any PDE5 inhibitor.
- Sudden visual or hearing loss.
- An erection lasting longer than four hours.
Guidelines For Proper Use
What should pharmacists tell patients who present with imported Zudena?
Confirm the product source and batch details and check for absolute contraindications, notably nitrate therapy.
Review concomitant medications for CYP3A4 interactions and advise a starting dose of 100 mg taken 30–60 minutes before sexual activity, not exceeding 200 mg in 24 hours.
Advise on storage: keep below 30°C, away from moisture and sunlight, and retain tablets in original blister packs.
- Counselling checklist for pharmacists: verify product authenticity, check contraindications, review interactions, explain dosing and storage, warn about serious adverse events and recommend Yellow Card reporting if required.
Provide a short patient leaflet template verbally: name (udenafil), dose instructions (100 mg, 30–60 mins before sex), do not combine with nitrates, common side effects and when to seek urgent help.
Encourage reporting of adverse events via the MHRA Yellow Card scheme and signpost patients to NHS sexual‑health services and NHS 111 for urgent concerns.
Delivery Across United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | England | 5–7 days |
| Birmingham | England | 5–7 days |
| Manchester | England | 5–7 days |
| Glasgow | Scotland | 5–7 days |
| Leeds | England | 5–7 days |
| Edinburgh | Scotland | 5–7 days |
| Liverpool | England | 5–7 days |
| Bristol | England | 5–7 days |
| Sheffield | England | 5–9 days |
| Newcastle | England | 5–9 days |
| Belfast | Northern Ireland | 5–9 days |
| Cardiff | Wales | 5–9 days |
| Leicester | England | 5–9 days |
| Nottingham | England | 5–9 days |
| Plymouth | England | 5–9 days |
